This week in Drug Discovery (4 – 8 May)
News round-up for 4 – 8 May by Bruno Quinney, Content Team at DDW.
This week, the FDA has advanced an initiative to implement real-time clinical trials. Elsewhere, UCB has made headlines for through an acquisition and its cancer research venture.
The top stories:
FDA moves towards real-time clinical trials
The US Food and Drug Administration has announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).
Read more…
Cancer research alliance to advance ‘life-changing’ therapies
Biopharmaceutical company UCB has announced a new multi-project alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons.
UCB to acquire IMIDomics’ Patient Insight Business
Global pharmaceutical company UCB has acquired the Patient Insights Business of IMIDomics, giving it access to a large, multi-omics dataset for immunology studies.
New malaria target could pave way for drug development
A previously undiscovered target for treating malaria could pave the way for a new generation of drugs, experts say.
FDA grants Fast Track Designation to ALS pill
Tazbentetol, developed by biopharmaceutical company Spinogenix, is a once-a-day pill with potential to restore synapses, the key connections between neurons that allow people to think, plan, remember and control movement.